The incidence of enterovirus 71 (EV71) infection has greatly increased in the Asian Pacific region since 1997. Several large outbreaks, caused by different subgenogroups of EV71, occurred with high rates of morbidity and a substantial number of deaths. In 2007, 58 cases of EV71 infection requiring hospitalization were reported in The Netherlands after a period of low endemicity of 21 years. These events triggered a study on the epidemiology of EV71 in The Netherlands. Genetic analysis of the VP1 capsid region of 199 EV71 isolates collected from 1963 to 2008 as part of enterovirus surveillance activities revealed a change in the prevailing subgenogroups over time. From 1963 to 1986 infections were caused by three different and successive lineages belonging to subgenogroup B (the novel lineage designated B0, as well as B1 and B2). In 1987, following a major epidemic the previous year, the B genogroup was replaced by genogroup C strains of lineages C1 and, later, C2. Analyses of the clinical data suggested that there were differences between infection with genogroup B and with genogroup C strains in terms of the age groups affected and the severity of illness. From comparative analysis with genomic data available in the public domain, we concluded that EV71 strain evolution shows a global pattern, which leads to the question of whether the recently emerged C4 lineage strains will also spread outside of Asia.
The genus Enterovirus of the family Picornaviridae consists of nine species of which five infect humans: poliovirus and human enterovirus A, B, C, and D. Together with 11 serotypes of coxsackievirus A, human enterovirus 71 (EV71) belongs to the human enterovirus A species. Human EV71 was first isolated in 1969, and from that time onward outbreaks of this virus have been described globally (38) . On the basis of VP1 nucleotide sequence comparisons, three genogroups have been distinguished: A, B, and C (4, 29) . Genogroup A includes only one strain (BrCr-CA-70) isolated in California in 1970 (4) . Genogroup B is more common and consists of the previously defined subgenogroups B1 to B5, and genogroup C consists of subgenogroups C1 to C5 (4) . Together with its close relative coxsackievirus A16, EV71 is the major causative agent of hand, foot, and mouth disease (HFMD) (usually in children of Ͻ5 years of age). EV71, however, is also associated with neurologic disease, including aseptic meningitis, poliomyelitis-like paralysis, brainstem encephalitis, and neurogenic pulmonary edema (6, 36) . The incidence of EV71 appears to have increased in the Asian Pacific region since 1997. Several large outbreaks of HFMD have occurred with high rates of morbidity and substantial numbers of deaths (5, 6, 8, 9, 11, 21, 25, 27-29, 36, 40, 42) . An association between genogroup and severity of disease has not yet been reported (4, 6) .
The increasing numbers of EV71 cases reported in Asia and the observation of an EV71 outbreak in The Netherlands in 2007 after a period of low endemicity of 21 years raised the question of whether the epidemiology of EV71 is changing.
Therefore, we did a detailed analysis of the epidemiological and genetic data on EV71 circulation in The Netherlands over a 45-year period (1963 to 2008) .
MATERIALS AND METHODS
Isolation of enteroviruses in The Netherlands. In The Netherlands only the severe, hospitalized cases of EV71 infection are diagnosed and reported as part of the national enterovirus surveillance system. Mild cases of EV71 infection are hardly reported since HFMD is not classified as a notifiable disease. Primary diagnosis for all enterovirus infections in The Netherlands is performed by virological laboratories that participate in the Weekly Sentinel Surveillance System of the Dutch Working Group on Clinical Virology. Fecal samples, throat swabs, and cerebrospinal fluid (CSF) samples are collected from children with systemic viral infection, varying from meningitis to gastrointestinal disorders. The clinical samples are cultured on combinations of enterovirus-sensitive cell lines: RD, tertiary monkey kidney, LLC-MK2, Vero, HEp-2, and various human fibroblast cell lines. Viral isolates with an enterovirus-characteristic cytopathic effect are confirmed as enteroviruses by an immunofluorescence test with broadly reactive monoclonal antibodies (Dako, CA) (41, 47) or by a specific PCR assay (32, 33) . Typing of enterovirus-positive isolates is locally performed by the virological laboratories by the use of serum neutralization tests with polyclonal typing pools (provided by the National Institute for Public Health and the Environment, RIVM, Bilthoven, The Netherlands) (46) . Cell cultures of nontyped and nontypeable isolates are routinely sent to the RIVM for typing and characterization and form the basis for the historical RIVM collection of EV71.
Review of historic collection at RIVM for representativeness. In order to determine if differences in the surveillance setup influenced the data and EV71 isolates collected, a review was done of the protocols and technical developments from the beginning of the surveillance data collection.
RNA extraction. Viral RNA was extracted from cell cultures using a MagNA Pure LC Total Nucleic Acid Isolation Kit with a MagNA Pure LC instrument (Roche Diagnostics, Almere, The Netherlands). Lysis was done by adding 100 l of cell culture to 400 l of lysis binding buffer (provided in the kit). Extraction was performed according to manufacturer's instructions. Viral RNA was eluted in 50 l of elution buffer.
EV71 PCR assay. The VP1 gene was amplified as two overlapping regions using the 159F (5Ј-ACYATGAAAYTGTGCAAGG-3Ј), 162R (5Ј-CCRGTAG GKGTRCACGCRAC-3Ј), 161F (5Ј-CTGGGACATAGAYATAACWGG-3Ј), and NP1Anew (5Ј-CCACYCTGAAGTTGCCCACG-3Ј) primers, which, except for NP1Anew, have been published previously (4) . The previously published NP1A primer did not align optimally with our EV71 reference strains.
Reverse transcriptions were performed to convert the viral RNA to cDNA. For this reaction, 5.0 l of the isolated viral RNA was incubated at 42°C for 60 min together with 1.0 l of 25 M antisense primer, 3.0 l of 10ϫ PCR buffer (pH 8.3) (100 mM Tris-HCl, 500 mM KCl), 1.8 l of 25 mM MgCl 2 , 2.0 l of 10 mM concentrations of the deoxynucleoside triphosphates, 1.2 l of 10 U/l avian myeloblastosis virus reverse transcriptase (Promega, Leiden, The Netherlands), 0.4 l of RNase inhibitor (Amersham, Life Science), and 15.6 l of H 2 O. The reaction was finished by incubation of the samples at 95°C for 5 min, followed by incubation on ice.
In total, 15 l of the cDNA was used for the PCR amplification, together with 3.5 l of 10ϫ PCR buffer, 1.8 l of 25 mM MgCl 2 , 1 l of 25 M forward primer, 0.4 l of 5 U/l Taq polymerase (Roche), and 28.3 l of water. The PCR was carried out for 1 cycle of 3 min at 94°C and 30 cycles of 45 s at 94°C, 45 s at 42°C, and 1 min at 68°C, with a final cycle of 7 min at 68°C. Amplicon size analysis was performed using gel electrophoresis. Purification of the PCR products was performed according to the manufacturer's protocol (QIAquick PCR Purification Kit; Qiagen).
Sequencing of the PCR products was carried out with an ABI Prism BigDye Terminator Cycle Sequencing Ready Reaction Kit, version 3.2 (Applied Biosystems, Foster City, CA) on an automated sequencer (Applied Biosystems model 3700) using the 159F, 162seq (5Ј-GTTATRTCTATRTCCCAGTT-3Ј), 161F, and NP1Anew primers.
Phylogenetic analysis. Editing of the sequence data was performed using Bionumerics software (Applied Maths BVBA, Sint-Martens-Latem, Belgium). Isolates were assigned to specific genogroups and subgenogroups according to previously defined nomenclature (4) . Phylogenetic dendrograms were generated by the neighbor-joining method (bootstrap analysis with 1,000 pseudoreplicate data sets) using TREECON software, version 1.3b (43) . The reference strains used in the phylogenetic analysis are presented in Table 1 .
Comparison with globally available data from systematic literature review. Data on the global presence of EV71 subgenogroups were derived by an extensive literature review using the Pubmed and Scopus literature databases.
During the first search, abstracts and/or their titles were screened for the terms "enterovirus 71," "enterovirus type 71," "hev71," "hev-71," "ev71," or "ev 71." During the second search articles were screened on the basis of their main keywords: "outbreaks," "genotype," or "phenotype." Alternatively, articles were screened on basis of their scope: "epidemiology," "classification," "genetics," "pathogenicity." A third search was performed during which titles were screened for the terms "outbreak*," "epidem*," "case*," "fatal," "evolution," "genotyp*" (title/abstract), "genogroup*" (title/abstract), "subgenogroup*" (title/abstract), "phenotyp*," "phylogen*," "typing," "types," "serotyp*," "identificat*," "characteri*," "genetic," "circulation," or "new". Articles that were selected on the basis of the first search in combination with the second search or third search were used for reviewing. Year and country of detection and subgenogroup were recorded and used for a comparative analysis with the epidemiology in The Netherlands.
Nucleotide sequence accession numbers. The nucleotide sequence data reported in this paper were deposited in the DDBJ/EMBL/GenBank nucleotide sequence databases under the accession numbers AB491212 to AB491220.
RESULTS

Isolation of EV71.
A review of the protocols and technical developments showed that diagnosis of EV71 has consistently been performed since 1963. Cell lines susceptible to EV71 and standardized serological typing reagents have been used throughout the years (24) . EV71 cannot be neutralized by these reagents and formed part of the untypeable cell cultures that were routinely submitted to the RIVM for typing during the entire study period. Monospecific typing sera against EV71 became available at the RIVM in 1977, and isolates that could not be typed in the years 1963 to 1976 were tested retrospectively. A representative selection of the isolates was included in the RIVM biobank.
Trends in EV71 reporting. Between 1965 and 2008, 346 EV71 isolates were identified (Fig. 1) . In total, 198 of these isolates (57%) from the same number of patients and 1 EV71 isolate from 1963 were stored and used in this study. Data on the origin of clinical samples, date of isolation, clinical presentation, and age of patient were obtained from the submission forms sent by the virological labs. In total, 55.3% of the EV71 isolates were obtained from feces; 15.1% were from throat swabs; 0.5% were from nose swabs; 3% were from fluid from vesicles on hands, feet, and mouth; and 0.5% were from CSF. For 25.6% of the isolates collected between 1982 and 2007, the sample origin was not known. In 1986 and in 2007 an increase in the number of cases of EV71 infection requiring hospitalization was reported. A mean EV71 isolation rate of 4.2% in 1986 and 6.3% in 2007 versus 0.5% in the preceding and following years indicates that these peaks are real.
Change of subgenogroup over time. The complete VP1 regions of 199 EV71 strains isolated in The Netherlands in the years 1963 to 2008 were sequenced successfully and were assigned to specific genogroups and subgenogroups on the basis of robust phylogenetic clustering with EV71 reference strains from the GenBank (4). Figure 2 shows the genetic relationships of Dutch isolates representative for the collection studied and the reference strains obtained from GenBank.
In total, 85 isolates clustered with reference strains of genogroup B, of which 28 isolates belonged to subgenogroup B1, and 47 isolates belonged to subgenogroup B2. The remaining 10 isolates from 1963 to 1967 formed a distinct cluster within genogroup B, with 90.51% homology to subgenogroups B1 and Seasonal distribution of EV71. The month of sampling was known for 168 EV71 isolates (82%). Cases of EV71 infection were reported throughout the year, with a peak in the summer months of June and July. A second, but smaller, peak was observed in September and October (Fig. 4) , including subgenogroups of both genogroup B and C. No difference in seasonal distribution could be observed between isolates belonging to genogroups B and C.
Clinical data. Clinical data were known for 78 children infected with EV71 of genogroup B (92%) and 62 children infected with EV71 of genogroup C (54%) ( Table 2 ). In both genogroups the major reported clinical manifestations were fever, meningitis or encephalitis, and gastrointestinal symptoms (diarrhea and vomiting). The number of cases of typical HFMD (vesicles on hand, feet, and in mouth) was low, as expected, since only hospitalized cases of EV71 infection are usually diagnosed and reported in The Netherlands. There was no indication of EV71-related fatalities for the patients of this study.
The majority of the children showed more than one clinical symptom. For statistical analysis, the children were therefore categorized to one of the following groups: children with neu- Table 2 ). Neurological complications were significantly more often reported among children infected with EV71 of genogroup B than among children infected with genogroup C (P ϭ 0.000; odds ratio, 9.57; 95% confidence interval, 4.13 to 22.63). Gastrointestinal disease appeared to be more associated with genogroup C infection (P ϭ 0.008; odds ratio, 3.12; 95% confidence interval, 1.27 to 7.89).
The age of children with EV71 infection was known for 166 children (genogroup B, n ϭ 72; genogroup C, n ϭ 94) (Fig. 5) . The age of children infected with EV71 of genogroup B (median of 24 months) was overall significantly higher than the age of children infected with EV71 of genogroup C (median of 5 months) (P ϭ 0.000, one-way analysis of variance). Comparison of the ages of children with neurological complications (n ϭ 62; median of 24 months) and children with other, milder symptoms (n ϭ 62; median of 13 months) showed that there was no significant difference in age (P ϭ 0.539, one-way analysis of variance), excluding a correlation between the high number of neurological cases among children infected with genogroup B and the significantly higher ages of these children.
Comparison with globally available data from systematic literature review. Data on the global presence of EV71 subgenogroups were derived by an extensive literature review. In total, 326 articles were selected on the basis of our search strategy, and of these 30 papers contained data meeting our criteria. These were finally used to record place and time of isolation and subgenogroup (Fig. 6) .
Except for some cases of genogroup B2 infection in Japan and Taiwan, no data were reported on EV71 infections in the Asian region before 1997. Reports on EV71 epidemiology outside of this region showed circulation of B1 and B2 strains in Europe, the United States, and Australia in the 1970s up to 1986/1987. In Japan subgenogroup B2 was observed until 1989. The shift of genogroup B to genogroup C infection observed in our country in 1987, followed by the prevalence of genogroup C1 and, later, C2, also occurred in the United States and Australia in the same period of time. Recent reports on EV71 circulation in the United Kingdom, Austria, and Norway confirmed analogous circulation of C1 and C2 strains. a The total number of children infected was 78 for subgenogroup B and 62 for subgenogroup B. The number of children with neurological complications was 55 (71%) and 13 (21%), respectively; the number with other complications was 23 (29%) and 49 (79%) for infection with subgroups B and C viruses, respectively.
b P values were calculated with a two-tailed Fisher's test on the basis of number of children for whom clinical data were available.
2830
VAN DER SANDEN ET AL. J. CLIN. MICROBIOL.
on October 2, 2017 by guest http://jcm.asm.org/ from 1963 onwards made it possible to generate a detailed and realistic overview of a period of 45 years. This enabled observation of a clear change of prevailing subgenogroups over time in The Netherlands. The new subgenogroup B0, which was detected during the 1960s, has not been described before as retrospective typing of EV71 strains isolated before the first description of the EV71 serotype in 1974 has not been done previously. The seasonal distribution of EV71-a peak in the summer months of June and July and a second, but smaller, peak in September and October-does not differ from that of all other enterovirus infections diagnosed in The Netherlands (24) . The majority of the EV71 strains included in this study were isolated from feces and throat swabs. Only one isolate (0.5%) was obtained from CSF. This is in line with the results of a previous study in which specimens from the gastrointestinal and respiratory tracts were shown to have higher diagnostic yields for EV71 than CSF (36) . Primary diagnosis of enteroviruses in CSF only from patients with neurologic disease results in an underestimation of the real number of EV71 infections.
Comparison of data on EV71 epidemiology in the public domain showed that the change in the prevailing subgenogroups (B1, B2, C1, and C2) and the shift of genogroup B to genogroup C infection occurred more or less simultaneously in Europe, the United States, and Australia. Since the first publications on EV71 in Asia in 1997, in addition to the strains found elsewhere, additional subgenogroups (B3, B4, C4, and C5) have been reported to cause large outbreaks with high rates of severe morbidity and mortality in this region only. The global nature of the epidemiology of some subgenogroups, however, raises the question of whether strains of the C4 and C5 lineages will also spread outside Asia. The epidemic of subgenogroup B2 infection in our country in 1986 was followed by a switch to a new genogroup (genogroup C), possibly driven by herd immunity against genogroup B. Recurrence of the same scenario for viruses of genogroup C (global epidemiology of C1 and C2) might imply that epidemics of subgenogroup C4 infections in other parts of the world will be unlikely and that there might be a switch to a new genogroup.
A change in the clinical presentation of EV71 infection over time has been suggested previously (3, 34) . This is the first time, however, that a clinical difference between EV71 lineages has been described showing more severe disease associated with the genogroup B strains. These results, however, should be interpreted with caution. Mild cases of infection with genogroup B might have been reported less frequently during the 1980s than infections with genogroup C in recent years, and the higher average age of people infected may have contributed to more severe illness. In our data set, however, there was no significant correlation between the high number of neurological cases among children infected with genogroup B and the significantly higher ages of these children. In addition, fatal and severe cases of EV71 infection have been reported to occur especially among children of Ͻ4 years of age, with an increase in the number of cases with decreasing age (7, 10, 16, 20) . During the outbreak of subgenogroup C4 infection in China in 2008, 63.6% of the Chinese children infected were Ͻ2 years of age, and 39% were Ͻ1 year of age (11) . More data on the age of children infected with EV71 of different subgeno- (11, 17, 18, 26) , Singapore (6, 8, 29, 30, 40) , Malaysia (1, 3, 5, 6, 13, 19, 29, 34, 36) , Japan (3, 12, 31) , and Taiwan (12, 22, 23, 25, 44 groups of B and C should be analyzed to verify differences in the age groups affected. It is not clear why the Asian Pacific region has experienced an increased incidence of EV71 infection since 1997. A change in clinical presentation could coincide with a change in the viral transmission pathway. A shift of neurological complications to gastrointestinal disease with vomiting and diarrhea, in combination with other epidemiological parameters like crowding, lack of sanitation, and climate, could enhance virus transmission and explain the high rates of morbidity during epidemics in the Asian Pacific region. An increased susceptibility of the population to EV71 infection could be another explanation for the increased incidence. A study in Taiwan showed that EV71 seroconversion rates between 1994 and 1997 (a year before the large outbreak in 1998) were significantly lower (3% to 4%) than the rates before 1994 (7% to 11%) (27) . As a consequence, the size of the susceptible population increased, potentially passing a critical threshold. It is of interest to study host susceptibility among the Dutch population before and after the large outbreaks in 1986 and 2007.
To our knowledge this is the first extensive description of EV71 epidemiology in Europe. This study suggests that the change in the circulating virus from genogroup B to genogroup C coincided with a change in clinical presentation and in age group affected. The epidemiology of EV71 subgenogroups B1, B2, C1, and C2 appeared to have a global nature, which implies that a subgenogroup C4 outbreak, as was observed in China in 2008, can be expected to occur in other parts of the world as well. Repeat of the 1986 scenario in The Netherlands would imply that new cases of severe EV71 infection will occur only after the introduction somewhere in the world of a new genotype virus, e.g., subgenogroup D (15) . In line with this scenario is the isolation of only one EV71 strain in The Netherlands in 2008 under surveillance regimen identical to that of the preceding years.
